1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2Department of Creative IT Engineering, Pohang University of Science and Technology (POSTECH), Pohang, Korea.
3Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
4Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea.
Copyright © 2020 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | Value |
---|---|
Age, yr | 63±14 |
Sex, male/female | 64 (61)/41 (39) |
BMI, kg/m2 | 23.89 (21.46–26.81) |
ICU/non-ICU patients | 43 (41)/62 (59) |
Duration of diabetes, yr | 5.50 (0.00–15.00) |
Type of diabetes | |
Type 1 diabetes mellitus | 3 (2.9) |
Type 2 diabetes mellitus | 87 (82.9) |
Steroid-induced or post-transplant | 15 (14.3) |
Prior treatment of diabetes | |
Oral glucose-lowering agents only | 36 (34.3) |
Insulin with or without oral agents | 38 (36.2) |
None or newly diagnosed diabetes | 31 (29.5) |
Chronic kidney disease (eGFR <60 mL/min/1.73 m2) | 31 (29.5) |
Reason for IV insulin therapy | |
Perioperative | 45 (42.9) |
Continuous enteral feeding | 20 (19.0) |
Diabetic ketoacidosis | 10 (9.5) |
NPO for other reasonsa | 30 (28.6) |
HbA1c (n=87), % | 8.5±2.4 |
C-peptide (n=36), ng/mL | 2.22 (1.06–4.20) |
Characteristic | Good responder: <6.0 hr (n=41) | Poor responder: ≥6.0 hr (n=50) | P value |
---|---|---|---|
Age, yr | 68.00 (55.00–76.50) | 66.00 (52.75–72.50) | 0.435 |
Sex, male/female | 24 (58.5)/17(41.5) | 33 (66.0)/17 (34.0) | 0.464 |
ICU/non-ICU patients | 13 (31.7)/28 (68.3) | 28 (56.0)/22 (44.0) | 0.020 |
BMI, kg/m2 | 24.20 (20.96–25.84) | 23.67 (21.05–26.95) | 0.646 |
Prior diagnosis of diabetes | 32 (78.0) | 32 (64.0) | 0.144 |
Duration of diabetes | 5.50 (0.25–18.50) | 4.00 (0.00–12.25) | 0.259 |
Type of diabetes | 0.549 | ||
Type 1 diabetes mellitus | 1 (2.4) | 2 (4.0) | |
Type 2 diabetes mellitus | 35 (85.4) | 38 (76.0) | |
Steroid-induced diabetes | 5 (12.2) | 10 (20.0) | |
Prior treatment for diabetes | 0.005 | ||
Oral agents only | 19 (46.3) | 9 (18.0) | |
Insulin±oral agents | 14 (34.1) | 18 (36.0) | |
None | 8 (19.5) | 23 (46.0) | |
Chronic kidney disease (eGFR <60 mL/min/1.73 m2) | 13 (31.7) | 15 (30.0) | 0.861 |
Reason for insulin infusion | 0.002 | ||
NPO for operation | 23 (56.1) | 9 (18.0) | |
Continuous enteral feeding | 7 (17.1) | 13 (26.0) | |
Diabetic ketoacidosis | 2 (4.9) | 7 (14.0) | |
NPO for other cause | 9 (22.0) | 21(42.0) | |
HbA1c, % | 8.21±2.38 | 8.51±2.35 | 0.585 |
C-peptide, ng/mL | 2.14 (1.78–3.59) (n=7) | 2.44 (1.09–4.56) (n=24) | 1.000 |
Factor | Adjusted odds ratio (95% CI) | P value |
---|---|---|
Model 1 | ||
Initial blood glucose | 1.017 (1.007–1.027) | 0.001 |
Prior treatment for diabetes | ||
Oral agents only | Reference | |
Insulin±oral agents | 2.355 (0.708–7.837) | 0.163 |
None | 6.751 (1.924–23.681) | 0.003 |
Model 2 | ||
Initial blood glucose | 1.027 (1.011–1.043) | 0.001 |
Change in blood glucose level at 2 hr (blood glucose at 2 hr-initial blood glucose) | 1.019 (1.002–1.036) | 0.026 |
Change in insulin infusion rate from baseline at 3 hr (insulin infusion rate at 3 hr–initial insulin infusion rate) | 1.747 (1.058–2.885) | 0.029 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). BMI, body mass index; ICU, intensive care unit; eGFR, estimated glomerular filtration rate; IV, intravenous; NPO, aGastrointestinal bleeding (
Values are presented as median (interquartile range), number (%), or mean±standard deviation. ICU, intensive care unit; BMI, body mass index; eGFR, estimated glomerular filtration rate; NPO,
CI, confidence interval.